Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
AA Nguyen, SB Habiballah, CD Platt, RS Geha… - Clinical …, 2020 - Elsevier
The COVID-19 pandemic is one of the greatest infectious challenges in recent history.
Presently, few treatment options exist and the availability of effective vaccines is at least one …
Presently, few treatment options exist and the availability of effective vaccines is at least one …
Efficacy of high-dose intravenous immunoglobulin in severe and critical COVID-19: a retrospective cohort study
R Aggarwal, A Dewan, A Pandey, N Trehan… - International …, 2022 - Elsevier
Background Various immunomodulatory therapies have been explored to manage the
dysregulated immune response seen in severe COVID-19 infection. The objective of this …
dysregulated immune response seen in severe COVID-19 infection. The objective of this …
Potential therapeutic approach of intravenous immunoglobulin against COVID-19
Z Kolahchi, H Sohrabi, S Ekrami Nasab… - Allergy, Asthma & …, 2021 - Springer
Since the outbreak of the novel coronavirus disease (COVID-19), the therapeutic and
management options to reduce the burden of the COVID-19 disease are under investigation …
management options to reduce the burden of the COVID-19 disease are under investigation …
High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia: the known mechanisms and clinical effects
X Liu, W Cao, T Li - Frontiers in immunology, 2020 - frontiersin.org
The current outbreak of viral pneumonia, caused by novel coronavirus SARS-CoV-2, is the
focus of worldwide attention. The WHO declared the COVID-19 outbreak a pandemic event …
focus of worldwide attention. The WHO declared the COVID-19 outbreak a pandemic event …
[HTML][HTML] Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching
C Huang, L Fei, W Li, W Xu, X Xie, Q Li… - International Journal of …, 2021 - Elsevier
Objectives At the present time, there is an absence of any proven effective antiviral therapy
for patients with coronavirus disease 2019 (COVID-19). The aim of this study was to assess …
for patients with coronavirus disease 2019 (COVID-19). The aim of this study was to assess …
Intravenous immunoglobulin therapy for critically Ill COVID-19 patients with different inflammatory phenotypes: a multicenter, retrospective study
Y Chen, J Xie, W Wu, S Li, Y Hu, M Hu, J Li… - Frontiers in …, 2022 - frontiersin.org
Background The benefits of intravenous immunoglobulin administration are controversial for
critically ill COVID-19 patients. Methods We analyzed retrospectively the effects of …
critically ill COVID-19 patients. Methods We analyzed retrospectively the effects of …
The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
CC Lai, WC Chen, CY Chen, YF Wei - Expert Review of Anti …, 2022 - Taylor & Francis
Objectives Severe-to-critical COVID-19 has been associated with exaggerated immune
responses, and anti-inflammatory agents including corticosteroid and interleukin-6 …
responses, and anti-inflammatory agents including corticosteroid and interleukin-6 …
Efficacy of IVIG (intravenous immunoglobulin) for corona virus disease 2019 (COVID-19): A meta-analysis
H Xiang, X Cheng, Y Li, W Luo, Q Zhang… - International …, 2021 - Elsevier
Background The benefit of IVIG (Intravenous Immunoglobulin) therapy for COVID-19
remains controversial. We performed a meta-analysis to investigate the efficacy of IVIG …
remains controversial. We performed a meta-analysis to investigate the efficacy of IVIG …
High-dose intravenous immunoglobulin in severe coronavirus disease 2019: a multicenter retrospective study in China
W Cao, X Liu, K Hong, Z Ma, Y Zhang, L Lin… - Frontiers in …, 2021 - frontiersin.org
Background The effective treatment of coronavirus disease 2019 (COVID-19) remains
unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in …
unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in …
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
MN Polizzotto, J Nordwall, AG Babiker, A Phillips… - The Lancet, 2022 - thelancet.com
Background Passive immunotherapy using hyperimmune intravenous immunoglobulin
(hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available …
(hIVIG) to SARS-CoV-2, derived from recovered donors, is a potential rapidly available …